Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001387131-21-012403 0001863769 XXXXXXXX LIVE 8 Common Stock, $0.001 par value per share 05/19/2026 false 0001348911 483497103 KalVista Pharmaceuticals, Inc. 200 Crossing Boulevard Framingham MA 01702 Jennifer Martin (206) 451-8040 1700 Seventh Ave, Suite 1120 Seattle WA 98101 0001863769 N Frazier Life Sciences Public Fund, L.P. b WC N DE 0.00 1249165.00 0.00 1249165.00 1249165.00 N 2.3 PN The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001879466 N FHMLSP, L.P. b AF N DE 0.00 1249165.00 0.00 1249165.00 1249165.00 N 2.3 PN The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001879465 N FHMLSP, L.L.C. b AF N DE 0.00 1249165.00 0.00 1249165.00 1249165.00 N 2.3 OO The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001790879 N Frazier Life Sciences X, L.P. b WC N DE 0.00 427983.00 0.00 427983.00 427983.00 N 0.8 PN The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001790880 N FHMLS X, L.P. b AF N DE 0.00 427983.00 0.00 427983.00 427983.00 N 0.8 PN The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001790811 N FHMLS X, L.L.C. b AF N DE 0.00 427983.00 0.00 427983.00 427983.00 N 0.8 OO The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001911592 N Frazier Life Sciences XI, L.P. b WC N DE 0.00 145592.00 0.00 145592.00 145592.00 N 0.3 PN The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001911580 N FHMLS XI, L.P. b AF N DE 0.00 145592.00 0.00 145592.00 145592.00 N 0.3 PN The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001911623 N FHMLS XI, L.L.C. b AF N DE 0.00 145592.00 0.00 145592.00 145592.00 N 0.8 OO The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0002052255 N Frazier Life Sciences XII, L.P. b WC N DE 0.00 6563.00 0.00 6563.00 6563.00 N 0.0 PN The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0002052246 N FHMLS XII, L.P. b AF N DE 0.00 6563.00 0.00 6563.00 6563.00 N 0.0 PN The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0002052177 N FHMLS XII, L.L.C. b AF N DE 0.00 6563.00 0.00 6563.00 6563.00 N 0.0 OO The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001341382 N James N. Topper b AF N X1 0.00 427983.00 0.00 427983.00 427983.00 N 0.8 IN The shares listed in rows 8, 10 and 11 represent shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. 0001365617 N Patrick J. Heron b AF N X1 0.00 427983.00 0.00 427983.00 427983.00 N 0.8 IN The shares listed in rows 8, 10 and 11 represent shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026. Common Stock, $0.001 par value per share KalVista Pharmaceuticals, Inc. 200 Crossing Boulevard Framingham MA 01702 This Amendment No. 8 ("Amendment No. 8") to Schedule 13D amends the statement on Schedule 13D filed on December 30, 2021 (the "Original Schedule 13D") as amended on January 26, 2022, December 30, 2022, December 14, 2023, February 22, 2024, November 7, 2024, August 20, 2025 and November 4, 2025 (the "Prior Amendments", and together with the Original Schedule 13D and this Amendment No. 8, the "Schedule 13D"). Except as otherwise specified in Amendment No. 8, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 8 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments. Item 2(a) is hereby amended and restated in its entirety to read as follows: The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron" and together with Topper, the "Members") Item 2(b) is hereby amended and restated in its entirety to read as follows: The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304 Item 2(c) is hereby amended and restated in its entirety to read as follows: FLSPF is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF. The sole business of FHMLSP, L.L.C. is to serve as general partner of FHMLSP, L.P. FLS X is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS X, L.P. is to serve as general partner of FLS IX. The sole business of FHMLS X, L.L.C. is to serve as general partner of FHMLS X, L.P. FLS XI is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XI, L.P. is to serve as general partner of FLS XI. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS XI, L.P. FLS XII is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XII, L.P. is to serve as general partner of FLS XII. The sole business of FHMLS XII, L.L.C. is to serve as general partner of FHMLS XII, L.P. The principal business of the Members is to manage FLSPF, FHMLSP, L.P., FHMLSP, L.L.C., FLS X, FHMLS X, L.P., FHMLS X, L.L.C., FLS XI, FHMLS XI, L.P., FHMLS XI, L.L.C., FLS XII, FHMLS XII, L.P., FHMLS XII, L.L.C. and a number of affiliated partnerships with similar businesses. Item 2(f) is hereby amended and restated in its entirety to read as follows: Entities: FLSPF - Delaware, U.S.A. FHMLSP, L.P. - Delaware, U.S.A. FHMLSP, L.L.C. - Delaware, U.S.A. FLS X - Delaware, U.S.A. FHMLS X, L.P. - Delaware, U.S.A. FHMLS X, L.L.C. - Delaware, U.S.A. FLS XI - Delaware, U.S.A. FHMLS XI, L.P. - Delaware, U.S.A. FHMLS XI, L.L.C. - Delaware, U.S.A. FLS XII - Delaware, U.S.A. FHMLS XII, L.P. - Delaware, U.S.A. FHMLS XII, L.L.C. - Delaware, U.S.A. Individuals: Topper - United States Citizen Heron - United States Citizen Item 3 of the Schedule 13D is hereby amended to incorporate Item 5(c) hereof and to replace the last paragraph with the following: The working capital of FLSPF, FLS X, FLS XI and FLS XII was the source of the funds for the purchase of the FLSPF Shares, the FLS X Shares, the FLS XI Shares and the FLS XII Shares. No part of the purchase price of the FLSPF Shares, the FLS X Shares, the FLS XI Shares or the FLS XII Shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the FLSPF Shares, the FLS X Shares, the FLS XI Shares or the FLS XII Shares. Item 5(a) is hereby amended and restated in its entirety to read as follows: The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLSPF directly holds 1,249,165 shares of the Issuer's Common Stock (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS X directly holds 427,983 shares of the Issuer's Common Stock (the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares. FLS XI directly holds 145,592 shares of this Issuer's Common Stock (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 6,563 shares of this Issuer's Common Stock (the "FLS XII Shares"). FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person. Except as set forth on Exhibit 10.1 of this Schedule 13D, none of the Reporting Persons has effected any transactions relating to the Ordinary Shares during the past 60 days. May 19, 2026 Exhibit 10.1 Transactions Relating to the Common Stock of the Issuer During the Past Sixty (60) Days Exhibit 99.1 Joint Filing Agreement Frazier Life Sciences Public Fund, L.P. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. 05/21/2026 FHMLSP, L.P. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. 05/21/2026 FHMLSP, L.L.C. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C. 05/21/2026 Frazier Life Sciences X, L.P. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P. 05/21/2026 FHMLS X, L.P. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P. 05/21/2026 FHMLS X, L.L.C. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C. 05/21/2026 Frazier Life Sciences XI, L.P. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. 05/21/2026 FHMLS XI, L.P. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. 05/21/2026 FHMLS XI, L.L.C. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C. 05/21/2026 Frazier Life Sciences XII, L.P. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P. 05/21/2026 FHMLS XII, L.P. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P. 05/21/2026 FHMLS XII, L.L.C. /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C. 05/21/2026 James N. Topper /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney 05/21/2026 Patrick J. Heron /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney 05/21/2026